Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty.
Abstract | OBJECTIVE: DESIGN: A double blind, placebo controlled, dose finding study. SETTING: Four academic and community hospitals in the Netherlands. PATIENTS: 64 patients with stable coronary artery disease undergoing elective percutaneous transluminal coronary angioplasty. INTERVENTIONS: 30 mg, 45 mg, and 60 mg of lefradafiban three times daily or placebo was given for 48 hours. MAIN OUTCOME MEASURES: The primary safety end point was the occurrence of bleeding, classified as major, minor, or insignificant according to the thrombolysis in myocardial infarction (TIMI) criteria. Efficacy indices included per cent fibrinogen receptor occupancy (FRO), ex vivo platelet aggregation, and plasma concentrations of fradafiban. RESULTS: Administration of lefradafiban 30, 45, and 60 mg three times daily resulted in a dose dependent increase in median FRO levels of 71%, 85%, and 88%, respectively. Inhibition of platelet aggregation was closely related to FRO. There were no major bleeding events. The 60 mg lefradafiban group had a high (71%) incidence of minor and insignificant bleeding. The incidence of bleeding was 44% in the 30 mg and 45 mg groups, compared with 9% in placebo patients. Puncture site bleeding was the most common event. The odds of bleeding increased by 3% for every 1% increase in FRO. CONCLUSIONS:
Lefradafiban is an effective oral glycoprotein IIb/IIIa receptor blocker. The clinical effectiveness of doses up to 45 mg three times daily should be investigated.
|
Authors | K M Akkerhuis, M J van Den Brand, C van Der Zwaan, H O Peels, H Suryapranata, L R van Der Wieken, J Stibbe, J Hoffmann, T Baardman, J W Deckers, M L Simoons |
Journal | Heart (British Cardiac Society)
(Heart)
Vol. 85
Issue 4
Pg. 444-50
(Apr 2001)
ISSN: 1468-201X [Electronic] England |
PMID | 11250974
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biphenyl Compounds
- Platelet Aggregation Inhibitors
- Platelet Glycoprotein GPIIb-IIIa Complex
- Prodrugs
- Pyrrolidines
- lefradafiban
- fradafiban
|
Topics |
- Administration, Oral
- Aged
- Angioplasty, Balloon, Coronary
- Area Under Curve
- Biphenyl Compounds
(administration & dosage, adverse effects, blood, pharmacokinetics)
- Coronary Disease
(therapy)
- Double-Blind Method
- Female
- Hemorrhage
- Hemostasis
- Humans
- Logistic Models
- Male
- Middle Aged
- Platelet Aggregation
- Platelet Aggregation Inhibitors
(administration & dosage, adverse effects, pharmacokinetics)
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors, metabolism)
- Prodrugs
(administration & dosage, adverse effects, pharmacokinetics)
- Pyrrolidines
(administration & dosage, adverse effects, blood, pharmacokinetics)
- Risk
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|